icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
Coadministration of Ritonavir with the HCV Protease Inhibitor Danoprevir Substantially Reduces Reactive Metabolite Formation Both In Vitro and In Vivo
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
P. Goelzer,1 P.N. Morcos,1 J.Q. Tran,2 B. Wen,1 N.S. Shulman,3 B.J. Brennan,1 J. Hammond,1 T. Singer,4 P. Smith1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Hoffmann-La Roche Inc. Palo Alto, CA, USA; 3Genentech, South San Francisco, CA, USA; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif